ERBB2 and breast cancer: A phase I clinical trial (NCT03366844 - recruiting) is evaluating the safety of 3 × 8 Gy radiation therapy to the primary BC in combination with pembrolizumab for TNBC and ER + HER2- BC, without the use of chemotherapy [50].